Targeting Microglia Via Nanotechnology: A Novel Strategy to Overcome Neuroinflammation in Major Depressive Disorder
Authors:
- Pablo R. da SilvaPablo R. da Silva
- Nayana M. M. V. BarbosaNBNayana M. M. V. Barbosa
- Joandra M. da Silva LeiteJLJoandra M. da Silva Leite
- Larissa P. AlvesLALarissa P. Alves
- Jéssica C. de AndradeJAJéssica C. de Andrade
- Allessya L. D. FormigaAFAllessya L. D. Formiga
- Ana Flávia C. UchôaAUAna Flávia C. Uchôa
- Luiza C. D. NeriLNLuiza C. D. Neri
- Adriana M. F. de Oliveira-GolzioAOAdriana M. F. de Oliveira-Golzio
- Francisco H. Xavier-JúniorFXFrancisco H. Xavier-Júnior
- Ricardo D. de CastroRCRicardo D. de Castro
- Cícero F. Bezerra FelipeCFCícero F. Bezerra Felipe
Preprint
- 28 July 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers — such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, magnetic nanoparticles, and liposomes — and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.Keywords
All Related Versions
This publication has 130 references indexed in Scilit:
- Microglial‐Biomimetic Memantine‐Loaded Polydopamine Nanomedicines for Alleviating DepressionAdvanced Materials, 2025
- Controlled Drug Release Systems for Cerebrovascular DiseasesAdvanced Therapeutics, 2024
- Evaluation of the Therapeutic Effect of Curcumin-Conjugated Zinc Oxide Nanoparticles on Reserpine-Induced Depression in Wistar RatsBiological Trace Element Research, 2023
- Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With DepressionJAMA Psychiatry, 2023
- Neuroinflammation in Acute Ischemic and Hemorrhagic StrokeCurrent Neurology and Neuroscience Reports, 2023
- Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteinsDrug Delivery and Translational Research, 2022
- Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium PerspectiveClinical Pharmacology & Therapeutics, 2022
- Glucose transporters in brain in health and diseasePflügers Archiv - European Journal of Physiology, 2020
- Dual Functions of Microglia in Ischemic StrokeNeuroscience Bulletin, 2019
- Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar DisorderMolecular Neurobiology, 2018